Equity Overview
Price & Market Data
Price: $2.33
Daily Change: +$0.0256 / 1.10%
Range: $2.23 - $2.38
Market Cap: $3,231,331
Volume: 4,072
Performance Metrics
1 Week: 9.93%
1 Month: -11.93%
3 Months: -30.17%
6 Months: -28.20%
1 Year: -46.30%
YTD: -33.00%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York.